Comparing the prevalence of metabolic abnormalities between male individuals with alcoholic and non-alcoholic fatty liver disease

Abstract

Abstract: Objective To compare the prevalence of metabolic abnormalities between individuals with alcoholic fatty liver disease (AFLD) and with non-alcoholic fatty liver disease (NAFLD).Methods The medical records from check-ups of male employees with ultrasound-diagnosed fatty liver disease in the Bao-Steel Group (Shanghai, China) were retrospectively analyzed. The prevalence of metabolic abnormalities, including obesity, hypertension, hypertriglyceridemia, hypercholesterolemia and diabetes mellitus, were compared between the individuals with AFLD and with NAFLD by multivariate logistic regression analysis. The clustering of multiple metabolic abnormalities (CMMA) was defined as having any three or more of metabolic abnormalities mentioned above, and its prevalence was also compared between two groups.Results The male individuals with AFLD (n=474) and with NAFLD (n=764) were identified. Obesity, hypertension, hypertriglyceridemia and diabetes mellitus in the individuals with AFLD were as prevalent as with NAFLD, but hypercholesterolemia was more prevalent in AFLD (OR = 1.469, 95%CI = 1.113-1.939, P=0.007). There was no significant difference in the prevalence of CMMA between two groups (OR = 1.270, 95%CI = 0.869-1.855, P=0.217). Both in the younger than 40 years old group and in the older than 60 years old group, there was no significant difference in the prevalence of CMMA between the individuals with AFLD and with NAFLD (54.3% vs. 46.2% and 79.6% vs. 75.7%, respectively, P>0.05 for both comparisons). But in the 40~60 years old group, CMMA was more prevalent in AFLD than in NAFLD (67.4% vs. 52.6%, P=0.001).Conclusion In these male employees, individuals with AFLD are similarly metabolically unhealthy as those with NAFLD. Hence, abundant efforts should also be made to identify and manage accompanying metabolic abnormalities in the treatment of AFLD.

Key words: Alcoholic fatty liver disease, Nonalcoholic fatty liver disease, Metabolic abnormalities, Prevalence

JI Lei, FAN Jian-gao, LI Feng. Comparing the prevalence of metabolic abnormalities between male individuals with alcoholic and non-alcoholic fatty liver disease[J]. Chinese Hepatolgy, 2021, 26(1): 60-63.

References

[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64: 73-84.
[2] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and Meta-analysis. Hepatology, 2019,70: 1119-1113.
[3] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67: 328-357.
[4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 2020, 73: 202-209.
[5] Sun K, Ren M, Liu D, et al. Alcohol consumption and risk of metabolic syndrome: a meta-analysis of prospective studies. Clin Nutr, 2014, 33: 596-602.
[6] Anuurad E, Shiwaku K, Nogi A, et al. The new BMI criteria for Asians by the regional office for the western Pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health, 2003, 45: 335-343.
[7] Fan JG, Li F, Cai XB, et al. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol, 2007, 22: 663-668.
[8] Li YM, Fan JG, Wang BY, et al. Guidelines for the diagnosis and management of alcoholic liver disease: update 2010. J Dig Dis, 2011, 12: 45-50.
[9] Kotronen A, Yki-Järvinen H, Männistö S, et al. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health, 2010, 10: 237.
[10] Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut, 2010, 59: 1410-1415.
[11] Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med, 2007, 120: 829-834.
[12] Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol, 2014, 20: 8393-8406.
[13] Dam-Larsen S, Becker U, Franzmann MB, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol, 2009, 44: 1236-1243.
[14] Kim HJ, Kim JH, Choe WH, et al. Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study. Clin Mol Hepatol, 2014, 20: 154-161.
[15] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005, 112: 2735-2752.
[16] Toshikuni N, Fukumura A, Hayashi N, et al. Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. J Clin Biochem Nutr, 2013, 52: 82-88.
[17] Haflidadottir S, Jonasson JG, Norland H, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol, 2014, 14: 166-175.